Goodman and Gilman's The Pharmacological Basis of Therapeutics. (Record no. 29536)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03876nam a22003017a 4500 |
| 001 - CONTROL NUMBER | |
| control field | 20241101201127.0 |
| 003 - CONTROL NUMBER IDENTIFIER | |
| control field | OCOLC |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20241104145749.0 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 241101b |||||||| |||| 00| 0 eng d |
| 020 ## - INTERNATIONAL STANDARD BOOK NUMBER | |
| International Standard Book Number | 1-26-425807-0 |
| International Standard Book Number | 978-1-26-425808-6 |
| International Standard Book Number | 978-1-26-425807-9 |
| International Standard Book Number | 1-26-425808-9 |
| 040 ## - CATALOGING SOURCE | |
| Transcribing agency | ddc |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | English |
| 100 ## - MAIN ENTRY--PERSONAL NAME | |
| Fuller form of name | Laurence Brunton |
| 222 ## - KEY TITLE | |
| Key title | absorption ACh acid action activity administration adrenergic receptor adverse effects agents agonist antidepressants antipsychotic aripiprazole associated atropine BBB benzodiazepines binding blockade blood-brain barrier brain Ca2+ channels carbamazepine cardiac catecholamines cells Chapter cholinergic clearance clinical clozapine CNS compounds concentrations CYPs decrease depolarization depression disease disorders dopamine dosage dose drug efficacy endothelial enzymes EPI epilepsy excretion FDA Figure function G protein GABA gene genetic GPCRs hepatic human hypertension increase inhibition inhibitors interactions K+ kinase levels levodopa Li+ ligand liver mechanisms mediated medications membrane metabolism metabolites mg microbiome modulators molecules muscarinic receptors Na+ nerve neurons neurotransmitter nicotinic oral pathways patients peripheral pharmacokinetics Pharmacol pharmacological phenobarbital phenytoin plasma potential presynaptic receptor agonists receptor antagonists reduced release renal response result risk schizophrenia seizures selective serotonin side effects signaling smooth muscle stimulation substrate subtypes subunits synaptic syndrome target therapeutic therapy tion tissues toxicity transporters treatment uptake variants vascular VMAT2 α β |
| 240 ## - UNIFORM TITLE | |
| Uniform title | Goodman and Gilman's The Pharmacological Basis of Therapeutics. |
| 245 ## - TITLE STATEMENT | |
| Title | Goodman and Gilman's The Pharmacological Basis of Therapeutics. |
| 250 ## - EDITION STATEMENT | |
| Edition statement | 14th Edition |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Place of publication, distribution, etc. | New York | |
| Name of publisher, distributor, etc. | McGraw Hill LLC | |
| Date of publication, distribution, etc. | 2023. |
| 300 ## - PHYSICAL DESCRIPTION | |
| Extent | 1664 Pages |
| Extent | Includes Index |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | A Doody's Core Title for 2023!<br/><br/>The landmark pharmacology reference—updated to reflect the latest research and developments in the field<br/><br/>For more than 50 years, Goodman & Gilman’s: The Pharmacological Basis of Therapeutics has represented the pinnacle of authority and accuracy in describing the actions and uses of therapeutic agents in relation to physiology and pathophysiology. The text's careful balance of basic science and clinical applications has guided thousands of health care practitioners and students to a clear understanding of the drugs essential to preventing, diagnosing and treating disease.<br/><br/>This Fourteenth Edition includes five new chapters, 600+ illustrations, and important content from 53 new contributors. More than a textbook, Goodman & Gilman’s is a working template for the effective and rational prescribing of drugs in daily practice.<br/><br/>Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, Fourteenth Edition features:<br/><br/>Five NEW chapters on:<br/><br/>-Pharmacovigilance<br/><br/>-The blood-brain barrier<br/><br/>-Cannabis<br/><br/>-Antibodies, immune checkpoint inhibitors, CAR-T cells, and other biological agents<br/><br/>-Gastrointestinal microbiome and drug response Expanded coverage of the use of genetic polymorphisms in designing appropriate therapies Revised and expanded chapter on pharmacodynamics and the molecular mechanisms of drug action 600+ color illustrations Drug Fact Tables summarizing clinical pharmacology Content Outline and Abbreviation List at the beginning of each chapter 50 NEW figures on mechanism of drug actions 53 NEW contributors NEW online updates<br/> |
| 600 ## - SUBJECT ADDED ENTRY--PERSONAL NAME | |
| General subdivision | Medical / Dentistry / General, Drug Therapy, Medical / Pharmacology, Pharmaceutical Preparations, Pharmacological Phenomena, Chemotherapy, Drugs, Pharmacokinetics. |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Fuller form of name | Bjorn Knollmann |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Source of classification or shelving scheme | ddc |
| Koha item type | E-BOOKS |
| Suppress in OPAC | |
| Withdrawn status | Lost status | Source of classification or shelving scheme | Damaged status | Not for loan | Home library | Current library | Date acquired | Coded location qualifier | Total checkouts | Barcode | Date last seen | Copy number | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | MWALIMU NYERERE LEARNING RESOURCES CENTRE-CUHAS BUGANDO | 11/01/2024 | S/OFFICE | 20241101201127.0 | 11/01/2024 | 20241101201127.0 | 11/01/2024 | E-BOOKS |